iBio plans to use the offering's net proceeds for general co...
iBio plans to use the offering's net proceeds for general corporate purposes, including R&D and working capital. The funds are expected to extend the company's cash runway through 2025. CEO Martin Brenner thanked healthcare specialist investors for their support.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more